Comparison of Radiologic Studies in Pediatric Patients with Crohn Disease and Ulcerative Colitis

2008 ◽  
Vol 103 ◽  
pp. S535-S536
Author(s):  
Deborah Flomenhoft ◽  
Joseph Auer ◽  
Houssam Mardini ◽  
Harohalli Shashidhar ◽  
Willem De Villiers
2004 ◽  
Vol 5 (7) ◽  
pp. 530-539 ◽  
Author(s):  
U Potočnik ◽  
I Ferkolj ◽  
D Glavač ◽  
M Dean

Author(s):  
Nathan S. Rubalcava ◽  
Natalie A. Moreno ◽  
Jeremy Adler ◽  
James D. Geiger ◽  
Ronald B. Hirschl ◽  
...  

PEDIATRICS ◽  
2007 ◽  
Vol 120 (6) ◽  
pp. e1418-e1425 ◽  
Author(s):  
N. Gupta ◽  
A. G. Bostrom ◽  
B. S. Kirschner ◽  
G. D. Ferry ◽  
H. S. Winter ◽  
...  

Neurology ◽  
2021 ◽  
Vol 96 (12) ◽  
pp. e1672-e1679
Author(s):  
Xiaoying Kang ◽  
Alexander Ploner ◽  
Nancy L. Pedersen ◽  
Sara Bandres-Ciga ◽  
Alastair J. Noyce ◽  
...  

ObjectiveTo evaluate the effects of long-term tumor necrosis factor (TNF) inhibition on the risk and age at onset of Parkinson disease (PD), we performed a 2-sample Mendelian randomization study using genome-wide association studies (GWAS) summary statistics.MethodsGenetic variants in the vicinity of TNFRSF1A, the gene encoding TNF receptor 1 (TNFR1), were identified as predictive of pharmacologic blockade of TNFR1 signaling by anti-TNF therapy, based on genetic associations with lower circulating C-reactive protein (CRP; GWAS n = 204,402). The effects of TNF-TNFR1 inhibition were estimated for PD risk (ncases/controls = 37,688/981,372) and age at PD onset (n = 28,568) using GWAS data from the International Parkinson's Disease Genomics Consortium and 23andMe, Inc. To validate variants as proxies of long-term anti-TNF treatment, we also assessed whether variant associations reflected anticipated effects of TNFR1 inhibition on Crohn disease, ulcerative colitis, and multiple sclerosis risk (n = 38,589-45,975).ResultsTNF-TNFR1 signaling inhibition was not estimated to affect PD risk (odds ratio [OR] per 10% lower circulating CRP = 0.99; 95% confidence interval [CI] 0.91–1.08) or age at onset (0.13 years later onset; 95% CI −0.66 to 0.92). In contrast, genetically indexed TNF-TNFR1 signaling blockade predicted reduced risk of Crohn disease (OR 0.75; 95% CI 0.65–0.86) and ulcerative colitis (OR 0.84; 95% CI 0.74–0.97) and increased multiple sclerosis risk (OR 1.57; 95% CI 1.36–1.81). Findings were consistent across models using different genetic instruments and Mendelian randomization estimators.ConclusionsOur findings do not imply that TNF-TNFR1 signaling inhibition will prevent or delay PD onset.Classification of EvidenceThis study provides Class II evidence that TNF-TNFR1 signaling inhibition is not associated with the risk or age at onset of PD.


2018 ◽  
Vol 177 (11) ◽  
pp. 1695-1695
Author(s):  
Ivana Copova ◽  
Ondrej Hradsky ◽  
Kristyna Zarubova ◽  
Lucie Gonsorcikova ◽  
Kristyna Potuznikova ◽  
...  

2017 ◽  
Author(s):  
Julia B. Greer ◽  
Miguel D. Regueiro

Inflammatory bowel disease (IBD) encompasses both ulcerative colitis and Crohn disease, and is characterized by recurrent bouts of inflammation of the gastrointestinal tract. IBD affects approximately 4 million people worldwide, and rates are gradually increasing. This review covers the etiology, epidemiology, definition and pathophysiology, extraintestinal manifestations, and other disease-related complications of IBD. Figures show the distribution of ulcerative colitis and Crohn disease by location, several colonoscopic photographs of patients with ulcerative colitis as well as those with Crohn disease, computed tomography images of patients with Crohn disease, small bowel follow-through and fluoroscopic spot images of a patient with chronic structuring Crohn disease, and a computed tomographic scan showing extraenteric manifestations of Crohn disease. Tables list the differential diagnosis of ulcerative colitis, types of infectious colitis, complications of IBD, diagnostic criteria of toxic colitis, physical signs of Crohn disease, differences between Crohn disease and ulcerative colitis, and common extraintestinal manifestations of IBD. This review contains 11 highly rendered figures, 7 tables, and 63 references.


2021 ◽  
Vol 160 (3) ◽  
pp. S2
Author(s):  
Ellen Cowherd ◽  
Matthew Egberg ◽  
Michael Kappelman ◽  
Xian Zhang ◽  
Millie Long ◽  
...  

2015 ◽  
Author(s):  
Edward L. Barnes ◽  
Jonathan S. Levine

Inflammatory bowel disease (IBD) is composed of two major subtypes, ulcerative colitis (UC) and Crohn disease (CD). These chronic disorders, characterized by inflammation of the gastrointestinal tract, demonstrate a variety of clinical features, including intestinal and extraintestinal manifestations during periods of relapse and remission over many years. This review examines the clinical features of IBD, including the extraintestinal manifestations and diagnosis. Figures include examples of images conducted via computed tomography (CT), magnetic resonance imaging, and position emission tomography (PET)/CT. Tables list the location frequencies of UC and CD at the time of diagnosis, extraintestinal manifestations of IBD, differential diagnosis of UC and CD, and clinical utility of fecal calprotectin in the evaluation and management of IBD. This review contains 4 highly rendered figures, 5 tables, and 48 references. 


Sign in / Sign up

Export Citation Format

Share Document